Q32 Bio (QTTB) Non-Current Deffered Revenue (2017 - 2022)

Q32 Bio's Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $354000.0 for Q1 2022.

• On a quarterly basis, Non-Current Deffered Revenue fell 90.06% year-over-year to $354000.0 in Q1 2022; TTM through Mar 2022 was $354000.0, a 90.06% decrease from a year earlier, with the FY2021 full-year figure at $1.2 million, down 96.4% from the prior year.
• Non-Current Deffered Revenue retreated to $354000.0 in Q1 2022 per QTTB's latest filing, from $1.2 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $32.1 million in Q4 2020 and bottomed at $354000.0 in Q1 2022.
• The 5-year median for Non-Current Deffered Revenue is $29.8 million (2020), against an average of $21.8 million.
• Across the five-year window, Non-Current Deffered Revenue climbed 6.64% in 2020 and sank 96.4% in 2021, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $30.8 million in 2018, then retreated by 1.98% to $30.1 million in 2019, then increased by 6.64% to $32.1 million in 2020, then sank by 96.4% to $1.2 million in 2021, then tumbled by 69.38% to $354000.0 in 2022.
• Per Business Quant, the three latest QTTB Non-Current Deffered Revenue figures stand at $354000.0 (Q1 2022), $1.2 million (Q4 2021), and $2.0 million (Q3 2021).